08:00 , Dec 17, 2015 |  BC Innovations  |  Tools & Techniques

RNA upgrades

RNA upgrades In recent years, researchers have responded to the need for better technologies for RNA-based therapies (See "It's an RNA World." SciBX: Science-Business eXchange (July 24, 2014)) by developing methods that improve their delivery,...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

Volanesorsen: Phase III started

Isis began a double-blind, placebo-controlled, international Phase III trial to evaluate 300 mg subcutaneous volanesorsen once weekly for 12 months in about 50 patients. Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif.   Product: Volanesorsen ( ISIS...
08:00 , Dec 7, 2015 |  BioCentury  |  Regulation

Action in amyloidosis

The Amyloidosis Research Consortium is following in the footsteps of another well-organized rare disease community by drafting a proposed FDA guidance that will reflect patients' priorities. The advocacy group also plans to qualify a cardiac...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS-SMNRx: Extension study started

Isis began the open-label, international SHINE extension study to evaluate 12 mg intrathecal ISIS-SMNRx in about 274 patients who have completed the double-blind, sham-controlled Phase III ENDEAR or CHERISH trials. In SHINE, infants who enrolled...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS 416858: Phase II started

Isis began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate 200 and 300 mg subcutaneous ISIS 416858 twice weekly for 2 weeks and then once weekly for 10 weeks in about 53 patients. Isis...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS-APO: Phase II data

A double-blind, international Phase II trial in 65 patients with high (>=50 mg/dL and <175 mg/dL) or very high (>=175 mg/dL) LPA levels showed that once-weekly 100-300 mg doses of subcutaneous ISIS-APO(a)Rx for 12 weeks...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

ISIS-APO: Phase I/IIa data

A double-blind, placebo-controlled Phase I/IIa trial in 50 patients with elevated LPA levels showed that single subcutaneous doses of ISIS-APO(a)-LRx led to mean and maximum reductions in LPA levels at day 30 of 26.2% and...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Biogazelle, Isis Pharmaceuticals deal

Biogazelle partnered exclusively with Isis to identify and validate targets to treat colon, liver and lung cancer. Isis will provide access to its antisense platform to Biogazelle for large-scale validation of therapeutic long non-coding RNA...
02:49 , Nov 10, 2015 |  BC Extra  |  Clinical News

Isis climbs on LPA data

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) jumped $6.90 (12%) to $62.77 on Monday after reporting that its ISIS-APO(a)Rx and ISIS-APO(a)-LRx significantly reduced lipoprotein(a) (LPA) in clinical trials to treat patients with high LPA levels. ISIS-APO(a)Rx is an...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

GSK2998728: Additional Phase II data

Additional data from 3 patients with TTR-related cardiomyopathy who completed 12 months of dosing in an investigator-initiated, open-label, U.S. Phase II trial showed that once-weekly 300 mg subcutaneous ISIS-TTRRx led to a mean reduction of...